1. GSK-3β and BDNF genes may not be associated with venlafaxine treatment response in Chinese of Han ethnicity.
- Author
-
Sun, Qianqian, Yuan, Fan, Ren, Decheng, Ma, Gaini, Yang, Fengping, Wu, Xi, He, Lin, and He, Guang
- Subjects
- *
SINGLE nucleotide polymorphisms , *MENTAL depression , *FALSE discovery rate , *ETHNICITY , *GENE frequency - Abstract
Purpose: Venlafaxine is one of the commonly prescribed antidepressants for major depressive disorder (MDD). Accumulated evidence revealed the involvement of glutamatergic system in the pathophysiology of MDD and antidepressant treatment. Methods: We recruited 193 MDD patients who have been taking venlafaxine for 6 weeks, and investigated whether single nucleotide polymorphisms (SNPs) in GSK-3β and BDNF were associated with treatment response. Nine SNPs were selected randomly depending on association studies. Efficacy of treatment was determined by 17-item Hamilton Rating Scale. Allele and genotype frequencies were compared between responders and nonresponders. Results: After adjusting the false discovery rate, no significant difference was observed between response and nonresponse groups in allele or genotype distributions after venlafaxine treatment for 6 weeks. Conclusion: Our results indicated that genetic variants in the GSK-3β and BDNF may not be associated with treatment response in MDD patients treated with venlafaxine. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF